Department of Biomedical Science and Engineering, Konkuk University, Seoul 05029, Republic of Korea.
Int J Mol Sci. 2024 Sep 4;25(17):9598. doi: 10.3390/ijms25179598.
Obesity-related metabolic disorders, including diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease, increasingly threaten global health. Uncontrolled inflammation is a key pathophysiological factor in many of these conditions. In the human body, inflammatory responses generate specialized pro-resolving mediators (SPMs), which are crucial for resolving inflammation and restoring tissue balance. SPMs derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) such as resolvins, protectins, and maresins hold promise in attenuating the chronic inflammatory diseases associated with lipid metabolism disorders. Recent research has highlighted the therapeutic potential of n-3 PUFA-derived metabolites in addressing these metabolic disorders. However, the understanding of the pharmacological aspects of SPMs, particularly in obesity-related metabolic disorders, remains limited. This review comprehensively summarizes recent advances in understanding the role of SPMs in resolving metabolic disorders, based on studies in animal models and humans. These studies indicate that SPMs have potential as therapeutic targets for combating obesity, as well as offering insights into their mechanisms of action.
肥胖相关的代谢紊乱，包括糖尿病、非酒精性脂肪性肝病（NAFLD）和心血管疾病，正日益威胁全球健康。在许多这类疾病中，失控的炎症是一个关键的病理生理因素。在人体中，炎症反应会产生专门的促解决介质（SPM），这对于解决炎症和恢复组织平衡至关重要。源自ω-3 多不饱和脂肪酸（n-3PUFAs）的 SPM，如 resolvins、protectins 和maresins，在减轻与脂质代谢紊乱相关的慢性炎症性疾病方面具有潜力。最近的研究强调了 n-3PUFA 衍生代谢物在解决这些代谢紊乱方面的治疗潜力。然而，对 SPM 药理学方面的理解，特别是在肥胖相关代谢紊乱方面，仍然有限。这篇综述全面总结了基于动物模型和人类研究中，对 SPM 在解决代谢紊乱中的作用的最新认识。这些研究表明，SPM 有作为治疗肥胖的靶点的潜力，并提供了对其作用机制的深入了解。
